31 August 2017, Amstelveen, The Netherlands: Adherium Limited (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, will be exhibiting at the 27th International Congress of the European Respiratory Society (ERS), being held at the MiCo Milano Congressi in Milan, Italy, from 9-13 September 2017.
Adherium will be exhibiting the latest iterations of its proprietary SmartInhaler™ platform at booth P.12 in Hall #3. The SmartInhaler™ device can improve adherence to many key medications, including AstraZeneca’s Symbicort combination therapy, for asthma and chronic obstructive pulmonary disease patients. The results of Adherium’s partnership with AstraZeneca will also be showcased at AstraZeneca’s booth L.01.
ERS is the largest meeting of respiratory professionals in the world, with a scientific and educational program designed to address the needs of researchers, clinicians, general practitioners and allied health professionals alike. Arik Anderson (CEO), Scott Fleming (SVP, Business Development Europe) and Nigel Devine (VP, Production and Development) will be attending the Congress.
Adherium is a provider of digital health solutions. The Company develops, manufactures and supplies patients, pharmaceutical companies, healthcare providers and contract research organizations with the broadest range of "smart" medication sensors for respiratory medications to address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium operates globally from bases in the USA, Europe and Australasia.
Adherium’s innovative Smartinhaler™ product platform integrates a Bluetooth enabled sensor and smartphone application to detect and record actual usage of inhaled medications. The Smartinhaler provides patients and physicians with critical data that can increase adherence to inhaled medication regimens, resulting in improved management of chronic respiratory conditions. Used in more than 70 projects and referenced in 65 peer reviewed journal articles, the Smartinhaler’s clinical outcomes data have proven that it can improve adherence by up to 59% in adults and 180% in children. These improvements were associated with a 60% reduction in severe respiratory episodes in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Smartinhaler has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software.
Adherium has a variety of Smartinhaler device configurations that are compatible with multiple medications, and the company is strongly positioned to realize the clinical and commercial value of its technology among key customers, including caregivers, insurers and hospitals. The company recently announced the sale of its 100,000th Smartinhaler.
Issued for and on behalf of Adherium by Instinctif Partners.
For more information please contact: email@example.com